Dr. Lambert is a regular researcher at the CHU de Québec-Université Laval Research Center and an assistant professor at the Faculty of Medicine of l’Université Laval in the department of Molecular Medicine. Dr. Lambert’s work aims to decipher how epigenetic regulators are assembled into functional units at the level of chromatin and how they impact transcription in healthy and cancerous cells. To address these fundamental questions, Dr. Lambert employs a multidisciplinary approach that includes mass spectrometry-based proteomics, protein biochemistry and cancer biology. He was recently awarded a prestigious Scholarship for the Next Generation of Scientists from the Cancer Research Society to support him as he establishes his research program.
Characterization of bromodomain-containing proteins in hormone-responsive cancers
Bromodomain-containing proteins are epigenetic regulators involved in many facets of the transcription process. Recently, numerous bromodomain inhibitors have been developed enabling the modulation of their activity for therapeutic benefit. Dr. Lambert’s group is currently investigating the functions of bromodomain-containing proteins in the context of hormone-responsive breast cancers to define their physical interplay with hormone receptors. In addition, Dr. Lambert is defining how specific cancer contexts impinged on bromodomain-containing proteins function and whether they generate actionable vulnerabilities that can targeted with bromodomain inhibitors.
Development of innovative functional proteomics technologies
To enable functional studies of epigenetic regulators, Dr. Lambert’s group is developing and implementing novel proteomics technologies to enable the study of proteomes, protein-protein interactions and post-translational modifications from clinically relevant samples. A particular focus of Dr. Lambert’s efforts remains the study of protein complexes associated with chromatin allowing the elucidation of the mechanisms enabling the ordered recruitment of epigenetic regulators to particular genomic loci.
2705, boulevard Laurier
R-4779
Québec, QC
Canada G1V 4G2
Latest news
- Quatorze chercheurs du CRCHU reçoivent près de 9 millions de dollars de subvention des IRSC 2020-02-28
- Équiper les scientifiques canadiens avec les meilleurs outils de recherche : 4 projets financés par le Fonds des leaders John-R.-Evans 2018-04-11
- 13 chercheurs se partagent plus de 800,000$ en subventions du CRSNG 2017-09-08
- Espinoza Romero, JeniferMaster studentCHUL+1 418-525-4444, extension 42296jenifer.espinoza-romero@crchudequebec.ulaval.ca
2705 Boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Kougnassoukou Tchara, Pata-EtingDoctoral studentCHUL+1 418-525-4444, extension 42296pata-eting.kougnassoukou-tchara.1@ulaval.capata-eting.kougnassoukou-tchara@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Linteau, NaomieDoctoral studentCHUL+1 418-525-4444, extension 42296naomie.linteau.1@crchudequebec.ulaval.canaomie.linteau.1@ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Linteau, NaomieMaster studentCHUL+1 418-525-4444, extension 42296naomie.linteau.1@crchudequebec.ulaval.canaomie.linteau.1@ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2 - Loehr, JérémyEmployeeCHUL+1 418-525-4444, extension 42296jeremy.loehr.1@ulaval.ca
2705, boulevard Laurier
R-4720
Québec, Québec
Canada G1V 4G2 - Saïdi, IsmaëlMaster studentCHUL+1 418-525-4444, extension 42296ismael.saidi@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-4720
Québec, QC
Canada G1V 4G2
ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers
Journal ArticleNat Commun, 15 (1), 2024.
The bromodomain acyl-lysine readers in human health and disease
Book ChapterChromatin Readers in Health and Disease, 35 , pp. 57-97, 2024, ISBN: 9780128233764.
DNA damage remodels the MITF interactome to increase melanoma genomic instability
Journal ArticleGenes Dev, 38 (1-2), 2024.
Structural insights into the human NuA4/TIP60 acetyltransferase and chromatin remodeling complex
Journal ArticleScience, 385 (6711), 2024.
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer
Journal ArticleMol Oncol, 17 (10), 2023.
Characterization of the Functional Interplay between the BRD7 and BRD9 Homologues in mSWI/SNF Complexes
Journal ArticleJ Proteome Res, 22 (1), 2023.
Multilevel interrogation of H3.3 reveals a primordial role in transcription regulation
Journal ArticleEpigenetics Chromatin, 16 (1), 2023.
Acetylation reprograms MITF target selectivity and residence time
Journal ArticleNat Commun, 14 (1), 2023.
The Identification of Nuclear FMRP Isoform Iso6 Partners
Journal ArticleCells, 12 (24), 2023.
Comprehensive Interactome Mapping of Nuclear Receptors Using Proximity Biotinylation
Journal ArticleMethods Mol Biol, 2456 , 2022.
Active projects
- Chromatin structure and function as a readout of physical interactions, from 2024-04-01 to 2029-03-31
- Covid-19 effects on ARTErial StIffness and vascular AgiNg (CARTESIAN) study- Canada, from 2021-06-01 to 2025-03-31
- Elucidation of bromodomain functions within SWI/SNF complexes, from 2020-04-01 to 2025-03-31
- Étude des interactions bromodomain-dépendantes et de leurs impacts sur le cycle de transcription, from 2022-07-01 to 2026-06-30
- Mitochondria bound to lipid droplets as new regulators of insulin resistance, from 2022-12-01 to 2025-11-30
- Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, from 2024-04-01 to 2030-03-31
- Régulation dynamique de la couronne fibreuse dans l'espace et le temps, from 2024-04-01 to 2027-03-31
- Tetrahymena thermophila - un model évolutionnaire divergent pour découvrir de nouveau modes de régulation transcriptionnelle, from 2022-03-15 to 2025-03-14
Recently finished projects
- Caractérisation du protéome mitochondrial de la prostate, from 2022-09-21 to 2023-03-31
- Characterization of the scaffolding roles of bromodomain containing proteins at the level of chromatin, from 2017-04-01 to 2024-03-31
- Investigating TBC1D9 therapeutic potential for triple negative breast cancer, from 2022-09-21 to 2023-03-31
- Structural characterization of full-length BET proteins and their functional implications to cancer, from 2022-09-01 to 2024-08-31
- TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29